crypto coin to invest in, Knowledge

The negotiation between Myriad and United Health Insurance may be extended to the beginning of 2025, and the negotiation between Myriad Genetics and UnitedHealthcare on the genetic test of Myriad may continue until the beginning of 2025. Myriad reiterated its estimate of the financial impact of the United Health Insurance Company's updated medical policy in 2024.Sarah Friar, CFO of OpenAI: Corporate customers will pay (at least) thousands of dollars for using artificial intelligence (AI) tools. In the end, it will be reasonable.Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)

The restricted shares with a market value of 463 million yuan were lifted today. Smith Barney, Foreign Service Holdings and Aimeike were among the top companies in terms of market value. On Wednesday (December 11th), the restricted shares of four companies were lifted, with a total lifting amount of 31.3389 million shares. According to the latest closing price, the total lifting market value was 463 million yuan. Judging from the amount of lifting the ban, one company lifted more than 10 million shares. Smith Barney Technology, Foreign Service Holdings and Pulitzer were among the top, with 24,446,500 shares, 6,503,200 shares and 234,800 shares respectively. Judging from the market value of lifting the ban, the number of shares lifted by a company exceeds 100 million yuan. Smith Barney Technology, Foreign Service Holdings and Aimeike are among the top companies in terms of market value, with market values of 392 million yuan, 34.8574 million yuan and 33.43 million yuan respectively. Judging from the proportion of shares released from the ban to the total share capital, the proportion of one company released from the ban exceeded 10%. Smith Barney Technology, Foreign Service Holdings and Aimeike are among the top companies, with the lifting rates of 29.38%, 0.28% and 0.05% respectively.Desai Siwei and Infineon jointly set up an innovative application center. Recently, the signing and unveiling ceremony of Desai Siwei-Infineon innovative application center and the signing ceremony of the memorandum of cooperation on intelligent driving domain control were held in Huizhou. At present, Desai Siwei and Infineon are relying on the Innovation Application Center to jointly define the MCU chip architecture of the future EEA, test the performance and evaluate the reliability of TC4x MCU devices, so as to provide innovative solutions to customers. In the future, Desai Siwei will join hands with Infineon to carry out joint technical research in two key areas: intelligent driving and cockpit, and accelerate the commercialization of more innovative product technical solutions.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.

Nikkei futures opened down 95 points at 39,290 on the Singapore Stock Exchange.Japanese manufacturers' confidence index turned negative to the central bank's forecast in December. A short-term survey in Reuters, Japan, found that Japanese manufacturers' business confidence deteriorated further in December due to concerns about US protectionist policies. The survey of 505 large Japanese non-financial enterprises showed that manufacturers' confidence index fell from 5 in November to -1 in December, which was the first time since last February, and the number of pessimists exceeded optimists for the first time in 10 months. The loss of business confidence may cast a shadow over the Bank of Japan's forecast. The Bank of Japan had previously predicted that a steady recovery driven by rising wages and consumption would help inflation reach the 2% target in a sustainable way and justify further interest rate hikes. Many manufacturing industries have reported that business confidence has declined. Among electronic machinery manufacturers, steel and non-ferrous metal manufacturers, pessimists far exceed optimists.One case of pre-application for residential land in Fengtai District, Beijing, with an initial total price of 4.008 billion yuan. According to official website of Beijing Municipal Planning and Natural Resources Committee, one case of pre-application for residential land in Fengtai District, Beijing, with an initial total price of 4.008 billion yuan. This plot is plot No.056 [2024], namely plot FT00-2404-0005 of the reconstruction project of the cold storage in the southwest suburb of Fengtai District, Beijing, with a land area of 27,422.21 square meters and a planned construction area of 69,104 square meters. The pre-application for this plot will be accepted from December 9, 2024 to January 7, 2025.